CXCR4 and cancer: Given that CXCR4 acts as an oncogene in ccRCC [39–42], and previous data suggested that CXCR4 also regulated drug resistance in cancer treatment [36,37], we validated that targeting CXCR4 was effective to improve DDP-sensitivity in ccRCC cells in the present study.